Next Article in Journal
Influence of the RelA Activity on E. coli Metabolism by Metabolite Profiling of Glucose-Limited Chemostat Cultures
Next Article in Special Issue
Computational Methods for Metabolomic Data Analysis of Ion Mobility Spectrometry Data—Reviewing the State of the Art
Previous Article in Journal
From Cycling Between Coupled Reactions to the Cross-Bridge Cycle: Mechanical Power Output as an Integral Part of Energy Metabolism
Previous Article in Special Issue
What mRNA Abundances Can Tell us about Metabolism
Article Menu

Export Article

Open AccessArticle
Metabolites 2012, 2(4), 701-716;

Differentiating Hepatocellular Carcinoma from Hepatitis C Using Metabolite Profiling

Department of Chemistry, Purdue University, 560 Oval Dr., West Lafayette, IN 47907, USA
Department of Surgery, IU School of Medicine, 550 University Blvd., UH 4601, Indianapolis, IN 46202, USA
Authors to whom correspondence should be addressed.
Received: 1 August 2012 / Revised: 12 September 2012 / Accepted: 25 September 2012 / Published: 10 October 2012
(This article belongs to the Special Issue Metabolism and Systems Biology)
Full-Text   |   PDF [455 KB, uploaded 15 October 2012]   |  


Hepatocellular carcinoma (HCC) accounts for most liver cancer cases worldwide. Contraction of the hepatitis C virus (HCV) is considered a major risk factor for liver cancer. In order to identify the risk of cancer, metabolic profiling of serum samples from patients with HCC (n=40) and HCV (n=22) was performed by 1H nuclear magnetic resonance spectroscopy. Multivariate statistical analysis showed a distinct separation of the two patient cohorts, indicating a distinct metabolic difference between HCC and HCV patient groups based on signals from lipids and other individual metabolites. Univariate analysis showed that three metabolites (choline, valine and creatinine) were significantly altered in HCC. A PLS-DA model based on these three metabolites showed a sensitivity of 80%, specificity of 71% and an area under the receiver operating curve of 0.83, outperforming the clinical marker alpha-fetoprotein (AFP). The robustness of the model was tested using Monte-Carlo cross validation (MCCV). This study showed that metabolite profiling could provide an alternative approach for HCC screening in HCV patients, many of whom have high risk for developing liver cancer. View Full-Text
Keywords: hepatocellular carcinoma; heptatitis C; metabolomics; NMR hepatocellular carcinoma; heptatitis C; metabolomics; NMR

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Wei, S.; Suryani, Y.; Gowda, G.A.N.; Skill, N.; Maluccio, M.; Raftery, D. Differentiating Hepatocellular Carcinoma from Hepatitis C Using Metabolite Profiling. Metabolites 2012, 2, 701-716.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Metabolites EISSN 2218-1989 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top